Literature DB >> 6291057

Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.

R F Irie, L L Sze, R E Saxton.   

Abstract

We established two long-term human B-lymphoblastoid cell lines (L55 and L72) transformed by Epstein-Barr virus that produced IgM kappa antibodies to the human tumor antigen, OFA-I. Periphral blood lymphocytes obtained from melanoma patients were used as the source of the B lymphocytes. Antibody specificity was determined by the immune adherence assay using various human cancer and noncancer tissues as targets. L55 antibody (designated anti-OFA-I-1) reacted with a variety of human tumor types whereas L72 antibody (designated anti-OFA-I-2) reacted only with tumor cells of neuroectodermal origin (melanoma, glioma, and neuroblastoma). The levels of IgM detected in the spent medium of 1 X 10(6) L55 and L72 cells were 4 and 9 micrograms/ml, respectively, by radioimmunoassay.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6291057      PMCID： PMC346965          DOI： 10.1073/pnas.79.18.5666

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  23 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Fetal neural antigens on human neuroblastoma cells.

Authors:  Y L Danon; R C Seeger; J E Maidman
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

3.  A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies.

Authors:  R Levy; J Dilley; R I Fox; R Warnke
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.

Authors:  K Irie; R F Irie; D L Morton
Journal:  Science       Date:  1974-11-01       Impact factor: 47.728

5.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.

Authors:  L Olsson; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.

Authors:  R F Irie; A E Giuliano; D L Morton
Journal:  J Natl Cancer Inst       Date:  1979-08       Impact factor: 13.506

7.  A membrane antigen common to human cancer and fetal brain tissues.

Authors:  R F Irie; K Irie; D L Morton
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

8.  Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Authors:  W G Dippold; K O Lloyd; L T Li; H Ikeda; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

9.  The allogeneic bisection of carrier-specific enhancement of monoclonal B-cell responses.

Authors:  S K Pierce; N R Klinman
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

10.  Oncofoetal antigen I: a target for immune cytolysis of human cancer.

Authors:  N Sidell; R F Irie; D L Morton
Journal:  Br J Cancer       Date:  1979-12       Impact factor: 7.640
View more
  24 in total

1.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  Human monoclonal antibody. Construction of stable clones reactive with human breast cancer.

Authors:  A J Strelkauskas; C L Taylor
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Requirements for growth of Epstein-Barr virus-transformed cells at low cell densities.

Authors:  R F Tiebout; R W Sauerwein; W G van der Meer; F van Boxtel-Oosterhof; W P Zeijlemaker
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Variation of calcium current during the cell growth cycle in mouse hybridoma lines secreting immunoglobulins.

Authors:  Y Fukushima; S Hagiwara; R E Saxton
Journal:  J Physiol       Date:  1984-10       Impact factor: 5.182

5.  Construction and testing of mouse--human heteromyelomas for human monoclonal antibody production.

Authors:  N N Teng; K S Lam; F Calvo Riera; H S Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

6.  Cell-surface antigens of melanoma recognized by human monoclonal antibodies.

Authors:  H Yamaguchi; K Furukawa; S R Fortunato; P O Livingston; K O Lloyd; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.

Authors:  T Takahashi; A Conforti; Y Kikumoto; D S Hoon; D L Morton; R F Irie
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 8.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

9.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Authors:  Y Hayashi; D S Hoon; M S Park; P I Terasaki; D L Morton
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.